| Literature DB >> 24833053 |
Annika Kouki1, Roland J Pieters2, Ulf J Nilsson3, Vuokko Loimaranta4, Jukka Finne5, Sauli Haataja6.
Abstract
Streptococcus suis is a Gram-positive bacterium, which causes sepsis and meningitis in pigs and humans. This review examines the role of known S. suis virulence factors in adhesion and S. suis carbohydrate-based adhesion mechanisms, as well as the inhibition of S. suis adhesion by anti-adhesion compounds in in vitro assays. Carbohydrate-binding specificities of S. suis have been identified, and these studies have shown that many strains recognize Galα1-4Gal-containing oligosaccharides present in host glycolipids. In the era of increasing antibiotic resistance, new means to treat infections are needed. Since microbial adhesion to carbohydrates is important to establish disease, compounds blocking adhesion could be an alternative to antibiotics. The use of oligosaccharides as drugs is generally hampered by their relatively low affinity (micromolar) to compete with multivalent binding to host receptors. However, screening of a library of chemically modified Galα1-4Gal derivatives has identified compounds that inhibit S. suis adhesion in nanomolar range. Also, design of multivalent Galα1-4Gal-containing dendrimers has resulted in a significant increase of the inhibitory potency of the disaccharide. The S. suis adhesin binding to Galα1-4Gal-oligosaccharides, Streptococcal adhesin P (SadP), was recently identified. It has a Galα1-4Gal-binding N-terminal domain and a C-terminal LPNTG-motif for cell wall anchoring. The carbohydrate-binding domain has no homology to E. coli P fimbrial adhesin, which suggests that these Gram-positive and Gram-negative bacterial adhesins recognizing the same receptor have evolved by convergent evolution. SadP adhesin may represent a promising target for the design of anti-adhesion ligands for the prevention and treatment of S. suis infections.Entities:
Year: 2013 PMID: 24833053 PMCID: PMC3960878 DOI: 10.3390/biology2030918
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
S. suis virulence genes with known phenotype in adhesion or interaction with host cells. The chromosomal locations of the genes in the genome of S. suis type 2 P1/7, GZ1 or ST1 [35] are indicated.
| GENE ID | GENE DESIGNATION | MUTANT PHENOTYPES |
|---|---|---|
| Regulators with phenotype in adhesion | ||
| SSU0944, SSU0945 | Two-component regulator, decreased adhesion to Hep-2 cells | |
| SSU1873 not functional in P1/7, SSGZ1_1897 in
| Orphan regulator, decreased adhesion to Hep-2 cells | |
| – | Orphan regulator, decreased binding to Hep-2 cells | |
| SSU0376 | Quorum sensing regulator, decreased adhesion | |
| SSU1789 | Negative transcriptional regulator, increased adhesion to Hep-2 cells | |
| SSU1191 | Orphan regulator, increased adhesion to Hep-2 cells | |
| SSU1202 | Carbon catabolite protein, decreased capsule thickness | |
| Modulators of adhesion | ||
| SSU0516, SSU0519, SSU0520, SSU0517, SSU0535 | Polysaccharide synthesis genes, increased adhesion of unencapsulated mutants | |
| SSU0596, SSU1448 | Cell wall modification, upregulated upon contact with endothelial cells | |
| Moonlighting or other cell wall proteins without signal sequence and known anchoring mechanism | ||
| SSU0187, SSGZ1_0184 | Dipeptidyl peptidase IV, fibronectin binding | |
| SSU1320 | Enolase, fibronectin and plasminogen binding, recombinant protein inhibits adhesion to Hep-2 cells | |
| SSU0153 | Recombinant protein inhibits bacterial binding to porcine tracheal rings and Hep-2 cells | |
| SSU1541 | 6-Phosphogluconate-dehydrogenase, recombinant protein inhibits bacterial binding to Hep-2 and HeLa cells | |
| SSU0157 | Glutamine synthetase, decreased adherence to the Hep-2 cells | |
| SSU1127 | Biofilm and Hep-2 cell adhesion | |
| SSU1311 | Fibronectin binding | |
| LPXTG-anchored proteins | ||
| SSU0925 | Anchoring of cell wall proteins | |
| SSU0879 | Degradation of IgA protecting mucosal surfaces | |
| SSU1474 (pseudo), SSUST1_ 1540 in
| Lipoprotein degradation | |
| SSU0757 | Subtilisin-like protease, induces secretion of cytokines and chemokines | |
| SSU1143 | Fibronectin/fibrinogen binding, reduced adhesion and invasion to Hep-2 cells | |
Galα1-4Gal-binding proteins a.
| Structure/Antigen a | Ligands | ||
|---|---|---|---|
| Adhesins | Toxins | ||
| GbO3 b | |||
| GbO4 | GalNAcβ1-
| ||
| GbO5 | GalNAcα1-3GalNAcβ1-
| ||
a For simplicity, blood group antigen P1, Galα1-4Galβ1-4GlcNAcβ1-4Galβ1-4Glcβ1-1'Cer, is not included in the table; b GbO3, GbO4 and GbO5 are abbreviations for globotria-, globotetra- and globopentaosylceramides.
Figure 1(a) Hydrogen bonding patterns of S. suis PN, S. suis PO [77] and E. coli PapG adhesins [88,89]. Black dashed lines indicate hydrogen bonds and grey dashed lines indicate possible weak hydrogen bonds. Hydrogen bond directionalities have been mapped for the E. coli PapG class I adhesin [90], which was later confirmed by structural analysis of a globotetraose:papG class II adhesin complex [91]. (HBA = hydrogen bond acceptor, HBD = hydrogen bond donor). Derivatization with urea and ether groups at O-3 of α-D-Gal [92] enhances affinity for S. suis PN and E. coli PapG, respectively (indicated with yellow ovals). Ether groups at O-2 of α-D-Gal enhance binding to S. suis PN (indicated with green oval). (b) Space-filling models of the globotriose trisaccharide with hydroxyl oxygens interacting with the three adhesins shown in light pink, which illustrates the different epitopes recognized. (Globotriose conformation taken from the globotetraose:papG class II adhesin complex; pdb id 1J8R.)
Inhibitory potencies of galabiose dendrimers against S. suis and E. coli adhesion (modified from [98]).
| Bacterial strain and inhibitor | Valency of dendrimer | Relative potency | Potency per sugar |
|---|---|---|---|
| Monovalent | 1 | 1 | 1 |
| Divalent, short spacer | 2 | 13 | 7 |
| Divalent, long spacer | 2 | 12 | 8 |
| Tetravalent | 4 | 250 | 63 |
| Octavalent | 8 | 310 | 39 |
| Octavalent PAMAM | 8 | 260 | 32 |
| Monovalent | 1 | 1 | 1 |
| Divalent | 2 | 50 | 25 |
| Tetravalent | 4 | 170 | 42 |
| Tetravalent galatriose c | 4 | 8 | 2 |
| Octavalent | 8 | 100 | 13 |
| Monovalent | 1 | 1 | 1 |
| Divalent, short spacer arms | 2 | 3 | 1 |
| Divalent, long spacer arms | 2 | 3 | 2 |
| Tetravalent | 4 | 8 | 2 |
| Octavalent | 8 | 43 | 5 |
| Octavalent PAMAM | 8 | 6 | 1 |
The IC50 values were determined in a surface plasmon resonance (SPR) assay [97]; relative potency = IC50 or the MIC of the monovalent inhibitor divided by that of the inhibitor in question; relative potency per sugar = relative potency/valency; b MIC values were determined in a hemagglutination assay [99]; c other inhibitors were galabiose derivatives.